Nov. 28, 2025 -- Algernon Health Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian healthcare company, announces the closing of the second tranche (the “Second Tranche”) of its non-brokered private placement (the “Offering”), previously announced on November 6, 2025, with the first tranche closed on November 14, 2025. Gross proceeds from the Second Tranche totaled CAD $210,000 from the sale of 3,000,000 units (the “Units”) at an issue price of CAD $0.07

Nov. 24, 2025 -- Ascentage Pharma Group International Inc. (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced the publication of clinical and translational data from a Phase Ib study (NCT03594422) on the Company’s novel drug, olverembatinib (HQP1351), in patients with gastrointestinal stromal tumors (GIST), b

Nov. 27, 2025 -- InnoCare Pharma (HKEX: 9969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the first patient has been dosed in the global Phase II clinical trial of its novel TYK2 inhibitor, Soficitinib (ICP-332), for the treatment of patients with prurigo nodularis in China. Soficitinib is a potent and selective TYK2 inhibitor that is being developed for the treatment of various T-cell related autoimmune di

Nov. 26, 2025 -- TOMI Environmental Solutions, Inc. (NASDAQ: TOMZ) announces substantial progress in its custom integration pipeline, currently valued at approximately $3 million, signaling significant momentum in the life sciences sector. The company reports ten active projects across its SteraMist Integrated System (SIS) and Custom Engineered System (CES) platforms, serving both new and existing customers. The advancement reflects TOMI's strategic positioning as a turnkey solution provider

Key step achieved in advancing HER-096 towards Phase 2 efficacy trial 26 November 2025: Herantis Pharma Plc (“Herantis”), a clinical-stage company developing disease-modifying therapies to stop the progression of Parkinson’s disease, today announces the successful completion of a six-month preclinical Good Laboratory Practice (GLP) toxicology study for its lead clinical asset, HER-096. The study demonstrated a favorable safety and tolerability profile, well aligned with the previous pre-clinica

Nov. 24, 2025 - Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the JS001sc-002-III-NSCLC study has met its primary endpoints. JS001sc-002-III-NSCLC is a multi-center, open-label, randomized Phase 3 clinical study comparing toripalimab injection (subcutaneous injection) (code: JS001sc) or toripalimab injection

Antibody levels remained well above baseline across all six serotypes and age groups sixth month after third yearly booster dose No safety concerns observed in any age group by an independent Data Monitoring Committee (DMC) Results confirm benefits of a yearly vaccination prior to each Lyme season November 26, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced positive final immunogenicity and safety data from Phase 2 study, VLA15-221, of Lyme disease vaccine candidate, VLA15

– Enlivex has adopted the world’s first RAIN prediction markets token digital asset treasury strategy, via RAIN token accumulation. – RAIN is a fully decentralized predictions and options protocol that redefines predictive market ecosystems and provides a powerful platform for on-chain market creation - built for transparency, automation, and community participation. – Mr. Matteo Renzi, former Prime Minister of Italy has joined the Enlivex Board of Directors. – Enlivex to continue clinical devel

Nov. 26, 2025 -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced that it will present one oral late breaking communication and two poster presentations featuring blarcamesine at t

The Company expects to initiate first-in-human study in early 2026, with initial data anticipated H2 2026 Clinical Trial Application (CTA) submission marks the advancement of Tangram’s GalOmic RNAi platform into clinical development Nov. 26, 2025 -- Tangram Therapeutics (‘Tangram’), a company committed to uniting computation and RNAi to make better medicines faster, today announced the submission of a Clinical Trial Application (CTA) to the Medicines and Healthcare products Regulatory Agency (